Drugmaker Novo wins EU clearance for Catalent buy
Novo Holdings, the parent company of Ozempic maker Novo Nordisk, has received EU approval to acquire US contract drugmaker Catalent. The availability of alternate suppliers and sufficient supply convinced the watchdog...To view the full article, register now.
Already a subscriber? Click here to view full article